The global healthcare landscape is increasingly focusing on rare, orphan diseases, where unmet medical needs represent both a clinical challenge and a significant market opportunity. Lymphangioleiomyomatosis (LAM), a rare lung disease that primarily affects women of childbearing age, has transitioned from a poorly understood condition to a target for sophisticated molecular therapies. https://www.databridgemarketresearch.com/